Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Current Assets for 4 consecutive years, with $485.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 13.73% to $485.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $485.1 million through Dec 2025, down 13.73% year-over-year, with the annual reading at $485.1 million for FY2025, 13.73% down from the prior year.
  • Current Assets for Q4 2025 was $485.1 million at Day One Biopharmaceuticals, down from $490.0 million in the prior quarter.
  • The five-year high for Current Assets was $581.0 million in Q3 2024, with the low at $326.0 million in Q1 2024.
  • Average Current Assets over 4 years is $451.4 million, with a median of $467.4 million recorded in 2023.
  • Peak annual rise in Current Assets hit 56.01% in 2025, while the deepest fall reached 15.67% in 2025.
  • Over 4 years, Current Assets stood at $347.9 million in 2022, then rose by 7.88% to $375.3 million in 2023, then soared by 49.85% to $562.3 million in 2024, then dropped by 13.73% to $485.1 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $485.1 million, $490.0 million, and $494.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.